KEYNOTE-564: Adjuvant Pembrolizumab in Renal Cell Carcinoma

Opinion
Video

Dr Pal discusses the study design and results of the KEYNOTE-564 trial, and Benjamin Gerendash, MSN, RN, AGACNP-BC, discusses the management of adverse events associated with pembrolizumab.

Recent Videos
1 expert in this video
1 expert in this video
4 experts are featured in this series.
Hope S. Rugo, MD, FASCO, is featured in this series.